Italy · Delayed Price · Currency is EUR DiaSorin Earnings Call Transcripts
Fiscal Year 2026
-
The five-year plan targets 6–8% CAGR through 2030, driven by specialty leadership in immuno- and molecular diagnostics, U.S. market expansion, and innovation in automation and precision medicine. Margin expansion and €1B free cash flow are expected, with disciplined capital allocation and strong ESG commitments.
-
Q1 2026 saw a 3% revenue decline at constant FX, mainly from weak flu season, China headwinds, and U.S. destocking, but immuno grew 1% and guidance for 5%-6% annual growth is maintained. Share buybacks and tariff changes impacted net debt and margins.
Fiscal Year 2025
-
2025 saw modest revenue growth, strong immuno performance in North America, and strategic shifts in China amid VBP pressures. 2026 guidance anticipates 5%-6% revenue growth, with profitability impacted by product launches, FX, and ongoing macroeconomic headwinds.
-
Revenues grew 3% year-over-year to EUR 900 million, with core business up 6% at constant FX. Immuno led growth, while Molecular and LTG faced regional and market headwinds. 2025 guidance was revised to 5% ex-COVID revenue growth and 33% EBITDA margin, with stabilization expected in China and continued product launches.
-
H1 2025 saw 5% revenue growth to EUR 619 million, with core business up 8% at constant FX and EBITDA margin at 35%. Immunodiagnostics and Molecular Diagnostics segments delivered strong growth, while China faced double-digit declines. 2025 guidance for 8% core revenue growth and 34% EBITDA margin is confirmed.
-
Q1 2025 saw 8% revenue growth and a 34% EBITDA margin, driven by strong immunodiagnostics and molecular segments, while COVID sales declined as expected. U.S. growth outpaced Europe, China remained challenging, and guidance for 2025 was confirmed.
Fiscal Year 2024
-
2024 saw revenue and profitability in line with guidance, driven by strong US and European immunoassay and molecular performance, while China remained weak. Guidance for 2025 targets 8% ex-COVID revenue growth and margin expansion, with continued deleveraging and robust product launches.
-
Q3 saw double-digit ex-COVID growth, with strong immuno and molecular performance, especially in the U.S. and Europe. Guidance for 2024 was raised, with continued challenges in China and LTG instrument sales, but robust cash flow and margin improvement support a positive outlook.
-
Q2 2024 delivered strong ex-COVID growth, led by immunoassay and molecular diagnostics, with robust US and European performance. Guidance for 2024 was raised, expecting 6–7% ex-COVID revenue growth and a 33% EBITDA margin, while new platforms like LIAISON Plex are gaining traction.